Alleviant Medical, Inc. develops minimally invasive medical devices for treating heart failure, specifically through a no-implant atrial shunt.

Relief Cardiovascular develops a transcatheter smart implant for managing heart failure, specifically targeting diuretic-resistant cases.

Alveron Pharma develops a drug, OKL-1111, to treat intracranial haemorrhage by reversing the effects of anticoagulants and platelet inhibitors.

Antag Therapeutics is a biopharmaceutical company developing treatments for obesity and cardiometabolic diseases, focusing on injectable therapies like their novel GIPR antagonist, AT-7687.

CorFlow Therapeutics AG develops and validates the CoFl system for diagnosing and treating Microvascular Obstruction (MVO) in heart attack patients.

XII Medical, Inc. develops innovative neuromodulation therapies for obstructive sleep apnea.